Abstract
AimsAs part of the care of breast cancer patients considered for trastuzumab, the measurement of LV ejection fraction (EF) pre-treatment is required. Current protocols recommend that EF is then repeated...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have